Aurora Completes Installation of High-Throughput Platform for Bristol-Myers Squibb | GenomeWeb

NEW YORK, Dec 21 - Aurora Biosciences said Thursday that Bristol-Myers Squibb’s Pharmaceutical Research Institute has validated Aurora’s ultra-high throughput screening system, the UHTSS Platform.

This is the first time one of Aurora’s development partners has validated a complete UHTSS Platform, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.